Book covered I hear and will close this Friday so sounds like will be scaling
Emerald had a very good year in 2019 with clinics in Australia expanding rapidly and the company’s first medical data deals completed with Zelda (Zelira) and Canopy Growth, the world’s largest cannabis company. In 2020, Emerald plans to open more clinics in Australia and its first in the UK. Emerald’s detailed data collection from patient cannabinoid treatments has now attracted a great deal of interest from potential partners. The FDA is actively closing down producers who do not have medical proof around their products (https://viewpoints.reedsmith.com/po...ctices-leads-to-yet-another-class-action-suit). Doctors are asking for medical evidence before widely prescribing and health insurers will only pay for products where there is data to demonstrate the effectiveness in patients. This puts Emerald in a very valuable position.
EMD Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
